2219. Treatment Uptake for Hepatitis C Virus Infection in the Veterans Affairs Healthcare System in the Era of Directly Acting Antiviral Agents: An ERCHIVES Study
Session: Poster Abstract Session: Hepatitis A, B, and C
Saturday, October 6, 2018
Room: S Poster Hall

Background: Knowledge about HCV treatment uptake, regimens and providers in the era of all-oral directly acting antiviral agents is critical for patients, providers, payers and policy makers. Our objective was to determine the number of persons initiated on HCV treatment over time, and trends in providers who initiate treatment

Methods: Among all HCV+ persons in ERCHIVES from 2001-2017, we identified all persons who initiated HCV treatment and medical specialty of the provider initiating treatment. Results were tabulated by VA fiscal year.

Results: A total of 108,133 persons were initiated on treatment. (Figure 1) Sofosbuvir-based regimens were the most commonly used regimens, accounting for nearly two-thirds of all DAA regimens. Gastroenterologists/hepatologist were the most common initiators of treatment in the pre-DAA era accounting for 26.7% of all prescriptions in 2001-2011 but only 10.3% in 2017. (Figure 2) Allied health professionals accounted for only 7.2% of treatment initiations in the 2001-2011 period but were the most frequent prescribers in 2017 (22.2%). Ratio of persons initiated on treatment to new HCV diagnoses reversed in 2013 for HCV monoinfected persons and in 2014 for HCV/HIV coinfected persons, with new treatment initiations far outnumbering new infections.

Conclusion: There has been a dramatic increase in HCV treatment uptake in the VA healthcare system with the approval of newer all-oral DAA regimens. Treatment paradigm appears to be shifting towards lesser gastroenterologists/hepatologists and more allied health professionals treating HCV.



Figure 1. New hepatitis C virus infection diagnoses and treatments initiated per month for Veterans with hepatitis C virus infection.

Figure 2. Proportion of patients treated by each specialty by year of treatment initiation (excludes those classified as “other” and “missing”).

Adeel Ajwad Butt, Professor of Medicine/Professor of Healthcare Policy and Research, Medicine, VA Pittsburgh Healthcare System, Pittsburgh, PA; Medicine, Weill Cornell Medical College, New York, NY, Peng Yan, MS, VA Pittsburgh Healthcare System, Pittsburgh, PA, Vincent Lo Re III, MD, MSCE, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, Obaid Shaikh, MD, Univesity of Pittsburgh, Pittsburgh, PA and ERCHIVES


A. Ajwad Butt, Gilead: Grant Investigator , Research grant .

P. Yan, None

V. Lo Re III, None

O. Shaikh, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.